Reshef, Ran

Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis

Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE

Liver physiology and pathologyChemokine receptors and signaling

Cited by 323

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

Wermke, M., Araujo, D. M., Chatterjee, M., Tsimberidou, A. M., Holderried, T. A. W., Jazaeri, A. A., Reshef, R., Bokemeyer, C., Alsdorf, W., Wetzko, K., et al. (2025) · Nature Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 73

Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies

Gordillo, C. A., Parmar, S., Blanco, M., Delille, E. M., Assal, A., Mapara, M., & Reshef, R. (2021) · Annals of Hematology

Hematopoietic Stem Cell TransplantationMultiple Myeloma Research and Treatments

Cited by 29